Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

AGEN

Agenus (AGEN)

Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AGEN
DateTimeSourceHeadlineSymbolCompany
09/19/20245:45AMPR Newswire (US)Contact The Gross Law Firm by November 5, 2024 Deadline to Join Class Action Against Agenus Inc.(AGEN)NASDAQ:AGENAgenus Inc
09/16/20245:45AMPR Newswire (US)The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Agenus Inc.(AGEN) ShareholdersNASDAQ:AGENAgenus Inc
09/13/202410:00AMBusiness WireBotensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024NASDAQ:AGENAgenus Inc
09/11/20242:25PMPR Newswire (US)AGEN INVESTOR ALERT: Edelson Lechtzin LLP Urges Agenus, Inc. (NASDAQ: AGEN) Shareholders to Seek Legal Counsel About the Pending Securities Fraud Class ActionNASDAQ:AGENAgenus Inc
09/09/20247:30AMBusiness WireBotensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024NASDAQ:AGENAgenus Inc
09/03/20247:30AMBusiness WireAgenus to Participate in September Investor ConferencesNASDAQ:AGENAgenus Inc
08/08/20244:49PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGENAgenus Inc
08/08/20244:47PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AGENAgenus Inc
08/08/20244:45PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
08/08/20244:45PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
08/08/20244:08PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AGENAgenus Inc
08/08/20247:00AMBusiness WireAgenus Announces Appointment of Tom Harrison to Board of DirectorsNASDAQ:AGENAgenus Inc
08/08/20247:00AMBusiness WireAgenus Reports Second Quarter 2024 Operational and Financial ResultsNASDAQ:AGENAgenus Inc
08/07/202410:58AMBusiness WireAgenus Publishes Seminal Study on Botensilimab’s Activity in Treatment-Resistant CancersNASDAQ:AGENAgenus Inc
08/02/20244:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGENAgenus Inc
07/26/20247:00AMBusiness WireAgenus to Provide Second Quarter 2024 Financial Report and Corporate UpdateNASDAQ:AGENAgenus Inc
07/18/20247:00AMBusiness WireAgenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal CancerNASDAQ:AGENAgenus Inc
06/28/202411:10AMBusiness WireSignificant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI ConferenceNASDAQ:AGENAgenus Inc
06/27/20247:30AMBusiness WireCancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical StudiesNASDAQ:AGENAgenus Inc
06/18/20244:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
06/18/20244:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
06/18/20244:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
06/18/20244:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
06/17/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGENAgenus Inc
06/17/20247:00AMBusiness WireAgenus Announces Appointment of Dr. Jennifer Buell to Its Board of DirectorsNASDAQ:AGENAgenus Inc
06/14/20244:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGENAgenus Inc
06/13/20245:15AMBusiness WireNature Medicine Reports Agenus’ Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50NASDAQ:AGENAgenus Inc
06/04/20247:30AMBusiness WireAgenus Announces Virtual Annual Shareholders MeetingNASDAQ:AGENAgenus Inc
05/30/20244:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGENAgenus Inc
05/24/20245:00PMBusiness WireAgenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:AGENAgenus Inc
 Showing the most relevant articles for your search:NASDAQ:AGEN